XII. APPENDICES Appendix 1 Listing of Investments by Fund New Leaf Ventures II, L.P. $ amounts in millions, as of March 31, 2014 Please refer to Endnotes 1,J,K,L,M and N in this Appendix. Gross Multiple Gross Vintage Realized Unrealized Total (Realized Multiple Company Sector Year Total Cost Value Value Value Portion) (Total) Gross IRR Acadia Phamaceuticals, Inc. Therapeutics 2012 $ 7.7 $ 19.4 $ - $ 19.4 2.51 2.51 581.9% Ambit Biosciences, Inc. Therapeutics 2013 $ 104 $ 11.1 $ - $ 11.1 1.06 1.06 13.1% Array Biopharma Inc. Therapeutics 2012 $ 9.0 $ 20.3 $ - $ 20.3 225 DDS 74.0% Audax Health Solutions, Inc. Convergence 2011 $ 3.8 §$ 125 $ 16 $ 14.1 - 3.68 105.6% Chimerix, Inc. Therapeutics 2011 $ 20.6 $ 27.0 $ 44.9 § 71.9 3.07 3.50 57.7% Epizyme, Inc. Therapeutics 2013 $ 34 §$ 6.8 $ - $ 6.8 2.03 2.03 1583.0% Glumetrics, Inc. Diagnostics & Infrastructure 2008 $ 10.7 $ : $ . $ - = : NM Intercept Pharmaceuticals, Inc. Therapeutics 2012 $ 10.5 $ 34.1 $ - $ 34.1 3.24 3.24 323.6% Kalidex Pharmaceuticals, Inc. Therapeutics 2011 $ 24 §$ 0.2 $ - $ 0.2 0.07 0.07 -91.6% MEI Pharma, Inc. Therapeutics 2012 $ 9.0 $ 10.2 $ 35.8 §$ 46.0 2.94 5.12 423.2% Presidio Pharmaceuticals, Inc. Therapeutics 2009 $ 11.0 6 $ = $ = $ = = = NM Synageva BioPharma Therapeutics 2009 $ 10.4 $ 75.7 $ - $ PDch. 7.30 7.30 103.3% Worldheart, Inc. Healthcare Devices 2008 $ 17.0 $ 18 $ = $ 1.8 0.11 0.11 NM Total Realized or Partially Realized Investments $ 125.9 § 219.2 §$ 82.3 §$ 301.5 2.01 2.39 40.6% eee Advanced Cell Diagnostics, Inc. Diagnostics & Infrastructure 2012 $ 9.0 $ - $ 90 $ 9.0 - 1.00 -0.4% Afferent Pharmaceuticals, Inc. Therapeutics 2009 $ 11.2 $ - $ 11.2 $ 11.2 - 1.00 0.0% Altura Medical, Inc. Healthcare Devices 2010 $ 10.7 $ - $ 83 §$ 8.3 - 0.77 -12.3% AwarePoint Corporation Convergence 2011 $ 12.8 $ - $ 14.1 $ 14.1 - 1.10 5.7% Calchan Holdings LTD Therapeutics 2011 $ 5.2 §$ - $ - $ - - - NM CardioKinetix, Inc. Healthcare Devices 2011 $ 12.0 $ - $ 12.0 $ 12.0 - 1.00 0.0% Convergence Ph